FTIS
REGN icon

First Trust Investment Solutions’s Regeneron Pharmaceuticals REGN Stock Holding History

First Trust Investment Solutions’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-229
Closed -$220K – 290
2024
Q1 		$220K Hold
229
– – 0.04% 231
2023
Q4 		$201K Buy
+229
New +$189K 0.04% 230

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

First Trust Investment Solutions's REGN Position: Q2 2024 in Review

First Trust Investment Solutions sold out of Regeneron Pharmaceuticals (REGN) in Q2 2024, closing a stake of 229 shares — an estimated $220K sold.

First Trust Investment Solutions first reported a position in REGN in Q4 2023 and held it in 2 quarters. The position peaked at $220K in Q1 2024. 1,331 funds tracked by Wall St. Rank hold REGN as of Q2 2024.

  • First Trust Investment Solutions reported no remaining Regeneron Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • First Trust Investment Solutions sold 229 Regeneron Pharmaceuticals shares in Q2 2024, an estimated $220K.
  • First Trust Investment Solutions first reported a position in Regeneron Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • First Trust Investment Solutions's Regeneron Pharmaceuticals position peaked at $220K in Q1 2024.
  • 1,331 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2024.

Based on First Trust Investment Solutions's 13F filing for Q2 2024, filed 14 Aug 2024.